Browsing Tag
CAR-T
8 posts
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care.
Cartesian Therapeutics reports 100% lupus response signal, setting up Descartes-08 for myositis expansion
Find out how Cartesian Therapeutics achieved a 100% lupus response and is driving Descartes-08 into myositis development today.
Is BioNTech finally breaking out of its COVID shadow? The case for its oncology comeback
Discover how BioNTech is transforming from COVID-19 pioneer to oncology powerhouse, led by ADC success and mRNA innovations. Read more now.
Belgium’s Celyad Oncology halts drug research as cash runs thin—will patents be enough?
Celyad Oncology ends R&D to conserve cash and pivot toward IP licensing. Find out why the Belgian biotech is betting on patents to stay afloat.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.
AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and…
Laurus Labs acquires stake in Indian CAR-T therapy developer ImmunoACT
Laurus Labs said that it has acquired a stake of 26.62% in Immunoadoptive Cell Therapy Private Limited (ImmunoACT),…
Thermo Fisher Scientific and JW Therapeutics forge strategic CAR-T therapy partnership in China
Thermo Fisher Scientific has entered into a significant agreement with Chinese cell therapy leader JW Therapeutics, granting non-exclusive…